Key result
TAVR in low-risk patients with symptomatic severe aortic stenosis is associated with similar short-term but increased intermediate-term mortality compared to SAVR.
Why the study?
Does TAVR improve mortality compared to SAVR in low-risk patients with symptomatic severe aortic stenosis?
Does TAVR improve mortality compared to SAVR in low-risk patients with symptomatic severe aortic stenosis?
SAVR remains the gold standard for low-risk patients with symptomatic severe aortic stenosis pending results from ongoing randomized trials.
Key Points TAVR in low‐risk patients is associated with a similar short‐term but an increased intermediate‐term mortality compared to SAVR. Off label TAVR use, the imperfect risk assessment by mean STS and logistic EuroSCORE, unrecognized PVL, and older TAVR platforms may explain some of results. Until further evidence from the PARTNER‐3, NOTION‐2, and the Medtronic Evolut Low Risk Trials, SAVR remains the gold standard for low‐risk patients with symptomatic severe aortic stenosis © 2017 Wiley Periodicals, Inc.
No takes yet. Share an insight, caveat, or question.
Çilingiroğlu et al. (2018) conducted a review in Symptomatic severe aortic stenosis in low-risk patients. TAVR vs. SAVR was evaluated on Short-term and intermediate-term mortality. TAVR in low-risk patients with symptomatic severe aortic stenosis is associated with similar short-term but increased intermediate-term mortality compared to SAVR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: